FDA Approved Changes to the Sustiva Label

Source: Midwest AIDS Training + Education Center
Published October 12, 2017

On October 12, 2017 the FDA approved changed to the Sustiva (efavirenz) package insert to:

  • Update information on hepatotoxicity in DOSAGE and ADMINISTRATION, WARNINGS AND PRECAUTIONS, ADVERSE REACTIONS and Patient Information sections.
  • Update CONTRAINDICATIONS and Patient Information sections with drug-drug interaction information on elbasvir and grazoprevir.
  • Update DRUG INTERACTIONS, Table 5 with information about hepatitis C antiviral agents

Click here to view announcement with more details (PDF).